In "Major Banks," CICC lowered the target price for CR MEDICAL to 4.06 yuan with a rating of "Outperform the Market."
CICC published a research report stating that CR MEDICAL (01515.HK) is steadily developing, actively implementing measures to reduce costs and improve efficiency, while also strengthening discipline. The firm maintains its net profit forecast for 2026 at RMB 499 million and adds a new net profit forecast for 2027 at RMB 510 million.
Due to the decline in the valuation of the H-share medical services sector, the firm has lowered the target price for CR MEDICAL by 18.8% to HKD 4.06, maintaining its "outperform the market" rating
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments